Article

Breaking Barriers in Lung Cancer Research: The Intriguing Connection between IL-1β and PD-1/PD-L1 Pathways

2023-06-27

Abstract excerpt

In the past decade, targeted therapies for solid tumors, including non-small cell lung cancer (NSCLC), have advanced significantly, offering tailored treatment options for patients. However, individuals without targetable mutations pose a clinical challenge, as they may not respond to standard treatments like immune-checkpoint inhibitors (ICIs) and novel targeted therapies. While the mechanism of action of ICIs se...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 3ba662cf-7f20-5221-bbfe-04b039a04487
DOI: 10.20944/preprints202306.1853.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Breaking Barriers in Lung Cancer Research: The Intriguing Connection between IL-1β and PD-1/PD-L1 PathwaysDOI 10.20944/preprints202306.1853.v1Read

Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutationsSemantic proximity Read

Predictive biomarkers for response to immune checkpoint inhibitors in lung cancer: PD-L1 and beyond.Semantic proximity Read

EGFR-Mutated Non-Small Cell Lung Cancer and Resistance to Immunotherapy: Role of the Tumor Microenvironment.Semantic proximity Read

PD-1/PD-L1 Axis in Lung Cancer.Semantic proximity Read

The efficacy and possible mechanisms of immune checkpoint inhibitors in treating non-small cell lung cancer patients with epidermal growth factor receptor mutation.Semantic proximity Read

Immunosurveillance and Immunoediting of Lung Cancer: Current Perspectives and Challenges.Semantic proximity Read

PD-L1 as a biomarker in NSCLC: challenges and future directionsSemantic proximity Read

Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system.Semantic proximity Read

PD-L1 Expression in NSCLC: Clouds in a Bright SkySemantic proximity Read

Current Immunotherapeutic Strategies Targeting the PD-1/PD-L1 Axis in Non-Small Cell Lung Cancer with Oncogenic Driver Mutations.Semantic proximity Read

Immunotherapy in non-small-cell lung cancer: a bridge between research and clinical practice.Semantic proximity Read

NSCLC: from tumorigenesis, immune checkpoint misuse to current and future targeted therapySemantic proximity Read